.: OKULISTYKA :.

Wydanie 3/2019
str. 9 - 11

Adalimumab (Humira) w leczeniu nieinfekcyjnych zapaleń błony naczyniowej

Adalimumab (Humira) in Noninfectious Uveitis Treatment

Mariola Dorecka^1,2, Katarzyna Gontarz^1,2, Wojciech Maruszczyk^1,2, Ewa Mrukwa-Kominek^1,2

¹Katedra Okulistyki, Klinika Okulistyki Katedry Okulistyki Wydziału Lekarskiego w Katowicach Śląskiego Uniwersytetu Medycznego w Katowicach
Kierownik: prof. dr hab. n. med. Ewa Mrukwa-Kominek
² Oddział Okulistyki Dorosłych, Uniwersyteckie Centrum Kliniczne im. prof. Kornela Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach
Kierownik: prof. dr hab. n. med. Ewa Mrukwa-Kominek

Summary: Most noninfectious uveitis appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti inflammatory drugs. Inflammatory uveitis is a difficult condition to treat. The therapy mainly uses corticosteroids and immunosuppressive and immunomodulatory drugs. Recently, a new class of drugs defined as “biologics” has been successfully used in the treatment of noninfectious uveitis. Very encouraging treatment results were obtained after use of a biological drug – adalimumab (Humira). Adalimumab is the human monoclonal antibody directed against tumor necrosis factor α (TNF-α). The use of adalimumab in the treatment of noninfectious uveitis provides the opportunity to reduce dose of corticosteroids and immunosuppressive and immunomodulatory drugs. The latter ones used chronically at high doses lead to many different complications. Adalimumab treatment controlled inflammation is effective and safe in adult and young patients as confirmed by numerous multicentre studies.

Słowa kluczowe: zapalenie błony naczyniowej, leki biologiczne, leki immunosupresyjne, czynnik martwicy nowotworów alfa, kortykosteroidy.

Keywords: uveitis, biological products, immunosuppressive therapy, tumor necrosis factor α, corticosteroids.

powrót